- Home
- ANL vs ICCC Comparison
ANL vs ICCC Comparison
Compare ANL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- ICCC
- Stock Information
- Founded
- ANL 2004
- ICCC 1982
- Country
- ANL Cayman Islands
- ICCC United States
- Employees
- ANL N/A
- ICCC N/A
- Industry
- ANL
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- ICCC Health Care
- Exchange
- ANL Nasdaq
- ICCC Nasdaq
- Market Cap
- ANL 61.8M
- ICCC 60.1M
- IPO Year
- ANL 2023
- ICCC 1987
- Fundamental
- Price
- ANL $1.79
- ICCC $5.92
- Analyst Decision
- ANL Hold
- ICCC
- Analyst Count
- ANL 1
- ICCC 0
- Target Price
- ANL N/A
- ICCC N/A
- AVG Volume (30 Days)
- ANL 11.6K
- ICCC 7.7K
- Earning Date
- ANL 09-23-2025
- ICCC 11-12-2025
- Dividend Yield
- ANL N/A
- ICCC N/A
- EPS Growth
- ANL N/A
- ICCC N/A
- EPS
- ANL N/A
- ICCC 0.20
- Revenue
- ANL N/A
- ICCC $28,274,756.00
- Revenue This Year
- ANL N/A
- ICCC N/A
- Revenue Next Year
- ANL N/A
- ICCC N/A
- P/E Ratio
- ANL N/A
- ICCC $30.55
- Revenue Growth
- ANL N/A
- ICCC 21.75
- 52 Week Low
- ANL $1.10
- ICCC $3.34
- 52 Week High
- ANL $3.89
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- ANL 60.76
- ICCC 41.72
- Support Level
- ANL $1.65
- ICCC $6.29
- Resistance Level
- ANL $1.91
- ICCC $6.42
- Average True Range (ATR)
- ANL 0.10
- ICCC 0.24
- MACD
- ANL 0.00
- ICCC -0.02
- Stochastic Oscillator
- ANL 58.02
- ICCC 1.82
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.